TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach ...

Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma Management AG and Evotec AG. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX ...

Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma Management AG and Evotec AG. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX ...

Its long-term returns have been outstanding. Yet eroding fundamentals and today’s prohibitive valuation imply tomorrow’s ...

Prior to Sandoz, Mr. Bond was Chief Financial Officer of Vifor Pharma and Evotec. He also served as Chair of the Audit Committee for Siegfried AG, a leading CDMO quoted on the SIX Swiss Exchange ...

Laut Wick erstellt die Mettler Entwickler AG bereits für mehrere Interessenten ... Kehrichtverbrennungsanlage, Vifor und «Sitter Valley», siehe Karte) «einen optimalen Platz gefunden».

JJ is an employee of Robarts Clinical Trials. BGF reports grant/research support from Millennium Pharmaceuticals, Merck, Tillotts Pharma AG, AbbVie, Novartis Pharmaceuticals, Centocor, Elan/Biogen, ...

DOJ's "JUST DOGE" team will work with DOGE to identify "cost-cutting measures." The Department of Justice is preparing for Elon Musk's Department of Government Efficiency to begin working with the ...

WASHINGTON – Attorney General Pam Bondi pledged in her Senate confirmation hearing to take politics out of the Justice Department and not weaponize the way it oversees a sprawling array of ...

CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.

This includes an estimated 8% growth for the CSL Behring division and around 3% for both the Seqirus and Vifor divisions. The initiation of coverage with an Overweight rating and a substantial ...